95 CHF CHF 95.00
AG-CR1-3619-M01010 mgCHF 95.00
AG-CR1-3619-M05050 mgCHF 250.00
|Synonyms||Jardiance; BI-10773; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol|
|Purity Chemicals||≥98% (HPLC)|
|Solubility||Soluble in DMSO. Slightly soluble in water or ethanol.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Keep cool and dry.|
|Use/Stability||Stable for at least 3 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Antidiabetic agent.
- Potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor. >300-fold selectivity over SGLT-1, 4, 5 and 6.
- SGLT-2 is found almost exclusively in the proximal tubules of nephronic components in kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE).
- Shown to preserves β cell mass and restore glucose homeostasis.
- BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus: I. Aires & J. Calado; Curr. Opin. Investig. Drugs 11, 1182 (2010)
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors: R. Grempler, et al.; Diabetes Obes. Metab. 14, 83 (2012)
- Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats: L. Thomas, et al.; Diabetes Obes. Metab. 14, 94 (2012)
- Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. L. Seman, et al.; Clin. Pharmacol. Drug Dev. 2, 152 (2013)
- The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review: J.B. McGill; Diabetes Ther. 5, 43 (2014) (Review)
- Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes: E.M. Lamos, et al.; Expert Opin. Investig. Drugs 23, 875 (2014) (Review)
- The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat: H.H. Hansen, et al.; J. Pharmacol. Exp. Ther. 350, 657 (2014)
- Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial: S. Kullmann, et al.; Diabetes Care (Epub ahead of print) (2021)